<?xml version="1.0" encoding="UTF-8"?>
<p>The social burden of fungal disease is massive with approximately more than 1.5 billion people affected by the fungal disease worldwide per annum. However, these invasive fungal infections are estimated to be the cause of about 1.5 million deaths per year, making this a noteworthy health problem (
 <xref rid="B17" ref-type="bibr">Bongomin et al., 2017</xref>). While flourishing in its most usual mode of growth, a biofilm of 
 <italic>C. albicans</italic> biofilm displays increased resistance to the available antifungal drugs. These persistent groups of cells are difficult to eradicate and, ever so often, accountable for treatment failures. There is a necessity to develop new strategies to exterminate and treat these emerging 
 <italic>C. albicans</italic> biofilm infections in the medical setting.
</p>
